KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Amortizatization of Intangibles (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Amortizatization of Intangibles data on record, last reported at $169.7 million in Q4 2025.

  • For Q4 2025, Amortizatization of Intangibles rose 6.82% year-over-year to $169.7 million; the TTM value through Dec 2025 reached $654.7 million, up 4.36%, while the annual FY2025 figure was $654.7 million, 4.36% up from the prior year.
  • Amortizatization of Intangibles reached $169.7 million in Q4 2025 per JAZZ's latest filing, up from $168.4 million in the prior quarter.
  • Across five years, Amortizatization of Intangibles topped out at $172.1 million in Q1 2022 and bottomed at $68.2 million in Q1 2021.
  • Average Amortizatization of Intangibles over 5 years is $150.8 million, with a median of $155.1 million recorded in 2023.
  • Peak YoY movement for Amortizatization of Intangibles: surged 152.37% in 2022, then fell 12.96% in 2023.
  • A 5-year view of Amortizatization of Intangibles shows it stood at $157.3 million in 2021, then dropped by 12.66% to $137.4 million in 2022, then rose by 10.31% to $151.6 million in 2023, then grew by 4.85% to $158.9 million in 2024, then increased by 6.82% to $169.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Amortizatization of Intangibles were $169.7 million in Q4 2025, $168.4 million in Q3 2025, and $162.1 million in Q2 2025.